Systematic Review and Meta-Analysis of the Efficacy and Tolerability of Nicotine Preparations in Active Ulcerative Colitis

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2304-2315

  Nikfar, Shekoufeh ^a,b   Ehteshami Ashar, Solmaz ^c   Rahimi, Roja ^d   Abdollahi, Mohammad ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Efficacy; Meta analysis; Nicotine preparations; Safety; Systematic review; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ENEMA; GLUCOCORTICOID; MERCAPTOPURINE; MESALAZINE; NICOTINE; PLACEBO; PREDNISOLONE; PREDNISONE;

CORTICOSTEROID THERAPY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART PALPITATION; HUMAN; META ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TASTE DISORDER; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; HUMANS; NICOTINE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 79951844315     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.004     Document Type: Review

References (34)

1. Baumgart D.C. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int 2009, 106:123-133.
2. Kucharzik T., Maaser C., Lügering A., et al. Recent understanding of IBD pathogenesis: Implications for future therapies. Inflamm Bowel Dis 2006, 12:1068-1083.
3. Rezaie A., Khalaj S., Shabihkhani M., et al. Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients. Ann N Y Acad Sci 2007, 1095:305-314.
4. Rezaie A., Parker R.D., Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: An epiphenomenon or the cause?. Dig Dis Sci 2007, 52:2015-2021.
5. Jahanshahi G., Motavasel V., Rezaie A., Hashtroudi A.A., Daryani N.E., Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004, 49:1752-1757.
6. Travis S.P. Review article: The management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 2004, 20(Suppl 4):88-92.
7. Nikfar S., Rahimi R., Rezaie A., Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009, 54:1157-1170.
8. Rahimi R., Nikfar S., Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 2007, 13:PI13-PI18.
9. Rahimi R., Nikfar S., Rezaie A., Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007, 52:2920-2925.
10. Logan R.F., Edmond M., Somerville K.W., Langman M.J. Smoking and ulcerative colitis. Br Med J (Clin Res Ed) 1984, 288:751-753.
11. van der Heide F., Dijkstra A., Weersma R.K., et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009, 15:1199-1207.
12. Mahid S.S., Minor K.S., Soto R.E., Hornung C.A., Galanduk S. Smoking and inflammatory bowel disease: A meta-analysis [published correction appears in Mayo Clin Proc. 2007;82:890]. Mayo Clin Proc 2006, 81:1462-1471.
13. Cosnes J. Tobacco in IBD: Relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004, 18:481-496.
14. Aldhous M.C., Prescott R.J., Roberts S., Samuel K., Waterfall M., Satsangi J. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease?. Inflamm Bowel Dis 2008, 14:1469-1482.
15. Zhang S., Petro T.M. The effect of nicotine on murine CD4 T cell responses. Int J Immunopharmacol 1996, 18:467-478.
16. Savoye G., Lerebours E. Toll-like receptor-4 signaling: A possible candidate pathway to support tobacco smoking effects in ulcerative colitis. Am J Gastroenterol 2008, 103:2947-2948.
17. Green J.T., Thomas G.A., Rhodes J., et al. Nicotine enemas for active ulcerative colitis-a pilot study. Aliment Pharmacol Ther 1997, 11:859-863.
18. Srivastava E.D., Russell M.A., Feyerabend C., et al. Transdermal nicotine in active ulcerative colitis. Eur J Gastroenterol Hepatol 1991, 3:815-818.
19. Sandborn W.J., Tremaine W.J., Offord K.P., et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997, 126:364-371.
20. Pullan R.D., Rhodes J., Ganesh S., et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994, 330:811-815.
21. Lakatos P.L., Szamosi T., Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly?. World J Gastroenterol 2007, 13:6134-6139.
22. Ingram J.R., Thomas G.A., Rhodes J., et al. A randomized trial of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol 2005, 3:1107-1114.
23. Perera D.R., Janeway C.M., Feld A., Ylvisaker J.T., Belic L., Jick H. Smoking and ulcerative colitis. Br Med J (Clin Res Ed) 1984, 288:1533.
24. Jadad A.R., Enkin M.W. Randomised Controlled Trials 2007, BMJ Books, London, United Kingdom. 2nd ed.
25. Thomas G.A., Rhodes J., Ragunath K., et al. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 1996, 8:769-776.
26. Guslandi M., Tittobello A. Outcome of ulcerative colitis after treatment with transdermal nicotine. Eur J Gastroenterol Hepatol 1998, 10:513-515.
27. Egger M., Smith G.D., Altman D.G. Systematic Reviews in Health Care: Meta-Analysis in Context 2001, BMJ Books, London, United Kingdom. 2nd ed.
28. McGrath J., McDonald J.W., MacDonald J.K. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2004, 4. CD004722.
29. Ingram J.R., Rhodes J., Evans B.K., Thomas G.A. Preliminary observations of oral nicotine therapy for inflammatory bowel disease: An open-label phase I-II study of tolerance. Inflamm Bowel Dis 2005, 11:1092-1096.
30. Lashner B.A., Hanauer S.B., Silverstein M.D. Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials. Dig Dis Sci 1990, 35:827-832.
31. Watson J.P., Lewis R.A. Ulcerative colitis responsive to smoking and to nicotine chewing gum in a patient with alpha 1 anti-trypsin deficiency. Respir Med 1995, 89:635-636.
32. Roth L.S., Chande N., Ponich T., Roth M.L., Gregor J. Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. World J Gastroenterol 2010, 16:232-236.
33. Thomas G.A., Rhodes J., Mani V., et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995, 332:988-992.
34. Guslandi M. Long-term effects of a single course of nicotine treatment in acute ulcerative colitis: Remission maintenance in a 12-month follow-up study. Int J Colorectal Dis 1999, 14:261-262.